Esophageal Squamous Cell Carcinoma Clinical Trials in Shanghai, Shanghai Municipality
13 recruitingShanghai, Shanghai Municipality, China
Showing 1–13 of 13 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC230 enrolled57 locationsNCT05319730
Recruiting
Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Gastric CancerEndometrial CancerHepatocellular Carcinoma+5 more
Seagen, a wholly owned subsidiary of Pfizer714 enrolled61 locationsNCT05208762
Recruiting
Phase 1
Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
Esophageal Squamous Cell Carcinoma (ESCC)
Shanghai Zhongshan Hospital60 enrolled1 locationNCT07317609
Recruiting
Phase 2
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Neoadjuvant TherapyEsophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital26 enrolled1 locationNCT07266493
Recruiting
Phase 2
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
Esophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital100 enrolled5 locationsNCT06637163
Recruiting
Phase 2
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
Esophageal Squamous Cell Carcinoma (ESCC)
Shanghai Chest Hospital52 enrolled1 locationNCT06709417
Recruiting
Phase 3
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
Resectable Esophageal Squamous Cell Carcinoma
Zhigang Li426 enrolled5 locationsNCT05043688
Recruiting
Phase 2
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Ruijin Hospital48 enrolled1 locationNCT06122493
Recruiting
Phase 2
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Esophageal Squamous Cell CarcinomaAdjuvant TherapyNeoadjuvant Chemoimmunotherapy
Guo Xufeng73 enrolled1 locationNCT06056336
Recruiting
Phase 2
Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)
Esophageal Squamous Cell Carcinoma
Fudan University128 enrolled2 locationsNCT05281003
Recruiting
Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell CarcinomaNeoadjuvant Chemoimmunotherapy
Shanghai Zhongshan Hospital40 enrolled1 locationNCT05740995
Recruiting
Not Applicable
Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
Esophageal Squamous Cell CarcinomaChemoradiotherapySurvival
Fudan University320 enrolled3 locationsNCT04519905
Recruiting
Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer
Esophageal Squamous Cell CarcinomaNSCLCThymic Epithelial Tumor
Shanghai Cancer Hospital, China500 enrolled1 locationNCT04522687